Annual Report 年報 2024 Annual Report 2024 年報 www.tianyuanhealthcare.com Mission Statement To invest in businesses with high growth potential so as to increase shareholder value. ✺ ⽎ 䤸鞴亥냖㘍⡬弋ⱱ╯哆ⳉ♓䬠냖罇典⧎⡬ ai1744894410397_China Tian Yuan_AR24_cover_OP.pdf 2 17/4/2025 ��8:53 | 主席報告書 | 2 | | --- | --- | | 財務摘要 | 5 | | 業務回顧 | 7 | | 企業管治報告 | 11 | | 董事會報告 | 23 | | 環境、社會及管治報告 | 33 | | 獨立核數師報告 | 53 | | 綜合損益表 | 58 | | 綜合損益及其他全面收入表 | 59 | | 綜合財務狀況表 | 60 | | 綜合權益變動報表 | 62 | | 綜合現金流量表 | 64 | | 綜合財務報表附註 | 66 | | 公司資料 | 144 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 二零二四年末期業績－公告 截至二零二四年十二月三十一日止年度之經審核綜合業績 中國天元醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公告本公 司及其附屬公司及聯營公司（「本集團」）截至二零二四年十二月三十一日止年度 （「二零二四年財年」）之綜合業績，連同比較數字列載如下。 1 董事會謹此公告本集團該年度之經審核綜合業績連同上年度之比較數字如下： 綜合損益表 截至二零二四年十二月三十一日止年度 | | | 二零二四年 | 二零二三年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 營業額 | 3 | 26,845 | 45,230 | | 銷售成本 | | (5,607) | ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 (Incorporated in the Cayman Islands with limited liability) (Stock Code: 557) CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （ 股 份 代 號：557） 二零二四年 中期財務報告 截至二零二四年六月三十日止六個月 目錄 | --- | --- | |--------------------------------------------------------------------------|-------| | | | | | | | 綜合損益表. . | 2 | | 綜合損益及其他全面收入表 .. | 3 | | 綜合財務狀況表 ... | 4 | | 簡明綜合權益變動報表 . | 6 | | 簡明綜合現金流量表 ... ... ... | 8 | | 簡明綜合中期財務報表附註 | 10 | | 管理層討論及分析 | 26 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致之任何損失承擔任何責任。 TIAN YUAN HEALTHCARE CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 （於開曼群島註冊成立之有限公司） （股份代號：557） 二零二四年中期業績－公告 截至二零二四年六月三十日止六個月之 未經審核綜合業績 業績 中國天元醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公告本公司、 其附屬公司及聯營公司（「本集團」）截至二零二四年六月三十日止六個月（「期 內」）之未經審核綜合業績，連同比較數字列載如下。 1 綜合損益表 截至二零二四年六月三十日止六個月 | --- | --- | --- | --- | |--------------------------------------------------------------------|-------|----------------------------- ...

Annual Report年報 2023 www.tianyuanhealthcare.com Annual Report 2023 年報 Mission Statement To invest in businesses with high growth potential so as to increase shareholder value. 使 命 投資於具高增值潛力之業務以提高股東價值。 | 主席報告書 | 2 | | --- | --- | | 財務摘要 | 4 | | 業務回顧 | 6 | | 企業管治報告 | 10 | | 董事會報告 | 22 | | 環境、社會及管治報告 | 32 | | 獨立核數師報告 | 53 | | 綜合損益表 | 59 | | 綜合損益及其他全面收入表 | 60 | | 綜合財務狀況表 | 61 | | 綜合權益變動報表 | 63 | | 綜合現金流量表 | 65 | | 綜合財務報表附註 | 67 | | 公司資料 | 148 | 2 中國天元醫療集團有限公司 • 年 報 2023 主席報告書 本人謹代表中國天元醫療集團有限公司（「本公司」） 董事（「董事」）會（ ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 （於開曼群島註冊成立之有限公司） （股份代號：557） 中國天元醫療集團有限公司 二零二三年末期業績－公佈 截至二零二三年十二月三十一日止年度之 經審核綜合業績 中國天元醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公佈本公 司及其附屬公司及聯營公司（「本集團」）截至二零二三年十二月三十一日止年度 （「二零二三年財年」）之綜合業績，連同比較數字列載如下。 1 董事會謹此公佈本集團該年度之經審核綜合業績連同上年度之比較數字如下： 綜合損益表 截至二零二三年十二月三十一日止年度 | | | 二零二三年 | 二零二二年 | | --- | --- | --- | --- | | | 附註 | 千港元 | 千港元 | | 營業額 | 3 | 45,230 | 54,216 | | 銷售成本 | | (17,285) ...

CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中國天元醫療集團有限公司 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 截至二零二三年六月三十日止六個月 | | | 截至六月三十日止六個月 | | | --- | --- | --- | --- | | | | 二零二三年 | 二零二二年 | | | 附註 | 千港元 | 千港元 | | | | （未經審核） | （未經審核） | | 營業額 | 4 | 23,768 | 24,984 | | 銷售成本 | | (9,483) | (8,335) | | 毛利 | | 14,285 | 16,649 | | 預期信貸虧損撥備 | | (814) | (692) | | 其他收益╱（虧損）淨額 | 5 | 718 | (6,570) | | 行政開支 | 6 | (23,103) | (29,400) | | 經營業務虧損 | | (8,914) | (20,013) | | 分佔聯營公司虧損 | | (154) | (68) | | 融資成本 | 7 | (1,815) | (2,119) ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致之任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中 國 天 元 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立之有限公司） 557 （股份代號： ） 二零二三年中期業績－公告 截至二零二三年六月三十日止六個月之未經審核綜合業績 業績 中國天元醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公告本公司、 其附屬公司及聯營公司（「本集團」）截至二零二三年六月三十日止六個月（「期 內」）之未經審核綜合業績，連同比較數字列載如下。 ...

Financial Performance - The company reported a net loss attributable to equity holders of approximately HKD 29 million for the fiscal year 2022, compared to a net loss of approximately HKD 16.9 million in the previous year, primarily due to the negative impact of COVID-19 on revenue from the Shanghai hospital[6]. - The investment holding segment recorded a total realized and unrealized gain of approximately HKD 36.1 million in fiscal year 2022, a significant increase from approximately HKD 1.7 million in the previous year, resulting in a profit before tax of approximately HKD 18.2 million[7]. - Revenue from the Shanghai hospital decreased significantly to approximately HKD 31.1 million in fiscal year 2022, down from HKD 66.7 million in fiscal year 2021, due to lockdowns and restrictions in Shanghai[8]. - The company’s basic loss per share for fiscal year 2022 was HKD 0.0728, compared to HKD 0.0422 in the previous year[11]. - The company reported a total revenue of HKD 54.2 million for fiscal year 2022, a decrease from HKD 94.6 million in fiscal year 2021[18]. - The company recorded a net loss of approximately HKD 40.3 million for the fiscal year 2022, compared to a net loss of approximately HKD 19.1 million in the fiscal year 2021, primarily due to the negative impact of COVID-19 on revenue from the Shanghai hospital[22]. - The investment holding segment reported a total net gain of approximately HKD 36.1 million for the fiscal year 2022, significantly up from approximately HKD 1.7 million in the fiscal year 2021[23]. - Revenue from the Shanghai hospital was approximately HKD 31.1 million in fiscal year 2022, down from approximately HKD 66.7 million in fiscal year 2021, with a net loss of approximately HKD 19 million[24]. - The company confirmed third-party loan interest income of HKD 16.5 million for fiscal year 2022, slightly down from HKD 16.8 million in fiscal year 2021[27]. Business Strategy and Expansion - The company plans to continue expanding its core business in cosmetic and medical services in China and other Asian markets, anticipating growth in consumer spending in the medical beauty industry[13]. - The company is actively seeking new business opportunities to diversify and increase revenue sources[16]. - The company aims to explore various short-term investment plans to improve investment returns using its cash reserves[15]. - The group aims to further develop and expand its core business in the medical and cosmetic surgery sectors in China and other Asian markets, anticipating growth in consumer spending in the Chinese medical beauty industry[37]. - The group will continue its lending and related businesses, adopting more cautious credit assessments and procedures in light of global economic disruptions and trade disputes[38]. Corporate Governance - The board of directors held 24 meetings in 2022, with attendance rates for executive directors ranging from 21/24 to 24/24[48]. - The company has a clear division of responsibilities between the chairman and the CEO, with the current chairman and CEO being the same person since November 4, 2022[50]. - Non-executive and independent non-executive directors serve a term of two years and must stand for re-election at the annual general meeting[53]. - The company ensures that all directors receive appropriate training and are provided with comprehensive onboarding materials upon their appointment[49]. - The board is actively seeking suitable candidates to share the responsibilities of the chairman and CEO to comply with governance codes[51]. - The company emphasizes the importance of effective communication with shareholders and encourages open discussions among directors[52]. - The board is responsible for approving strategic plans, significant operational matters, investments, and loans, while also reviewing financial performance[47]. - Independent non-executive directors have attended various committee meetings, with attendance rates for some reaching 100%[48]. - The company has established a culture of ethical and responsible conduct, which is reinforced throughout the organization[47]. - The chairman plays a crucial role in ensuring that all directors are adequately informed and that board meetings are effective[52]. Risk Management and Internal Control - The company has established a robust risk management and internal control system aimed at achieving strategic goals and protecting shareholder investments[70]. - The risk management framework includes a three-tier structure involving the board, senior management, and business function management[71]. - The company conducts annual risk assessments to identify potential strategic, operational, financial, and compliance risks[75]. - An independent internal audit function regularly reviews the effectiveness of the company's risk management and internal control measures[77]. - The board is satisfied with the effectiveness and adequacy of the current risk management and internal control systems[78]. Environmental, Social, and Governance (ESG) Initiatives - The company has implemented a top-down management approach for ESG management and established effective ESG management systems and processes[147]. - The company reported a total greenhouse gas emission of 235,831.65 kg in 2022, a slight decrease from 240,598.67 kg in 2021[162]. - The company generated 3.42 grams of sulfur dioxide (SOx) emissions in 2022, an increase from 1.85 grams in 2021[160]. - The nitrogen oxides (NOx) emissions rose to 289.09 grams in 2022, compared to 62 grams in 2021[160]. - The company utilized 235,213 kg of carbon dioxide (CO2) emissions from purchased electricity in 2022, down from 240,258 kg in 2021[162]. - The company engaged in various stakeholder communications to enhance its ESG strategies and identify improvement opportunities[153]. - The company emphasized the importance of stakeholder feedback in shaping its sustainable development initiatives[155]. - The company has committed to reducing emissions through energy efficiency and the use of cleaner energy sources[161]. - The company has implemented policies to manage waste and emissions in compliance with relevant environmental regulations[156]. - The company identified occupational health and safety, product quality management, and operational compliance as key ESG focus areas during the reporting period[155]. Employee Management and Turnover - The overall employee turnover rate for the group in 2022 was 78%, a significant increase from 11% in 2021[196]. - The turnover rate for male employees in 2022 was 60%, compared to 8% in 2021, while for female employees it was 87%, up from 12%[196]. - The turnover rate for employees aged 18-25 reached 150% in 2022, compared to 13% in 2021[196]. - The group has a total of 111 employees as of December 31, 2022, down from 112 in 2021[183]. - The group has implemented a comprehensive learning and development plan to enhance employee skills and retention[182]. - The group emphasizes compliance with environmental regulations and has taken steps to ensure supply chain stability amid climate change risks[180]. - The group encourages the use of natural and pollution-free materials in beauty products to promote environmental sustainability[180]. - The group has expanded its supplier network to mitigate the impact of extreme weather on logistics and quality[180]. Health and Safety Measures - The company emphasizes the health and safety of both customers and employees, implementing various healthcare plans including regular preventive health check-ups and medical insurance[198]. - The company adheres strictly to relevant laws and regulations regarding occupational health and safety, particularly in the medical beauty sector, ensuring compliance with multiple national standards[199]. - To mitigate the risk of infection during surgeries, the company mandates medical staff to wear protective gear, including impermeable gloves and masks, and conducts monthly training on infection control[199]. - The company has established multiple infection prevention measures in response to COVID-19, including regular nucleic acid testing for employees and disinfection facilities in public areas[200]. - The vaccination completion rate for medical staff reached 100% for the third dose during the year, highlighting the company's commitment to employee health[200].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容所產生或因 倚賴該等內容而引致之任何損失承擔任何責任。 CHINA TIAN YUAN HEALTHCARE GROUP LIMITED 中 國 天 元 醫 療 集 團 有 限 公 司 （於開曼群島註冊成立之有限公司） 557 （股份代號： ） 二零二二年末期業績－公佈 截至二零二二年十二月三十一日止年度之 經審核綜合業績 中國天元醫療集團有限公司（「本公司」）董事（「董事」）會（「董事會」）公佈本公司 及其附屬公司、合營安排及聯營公司（「本集團」）截至二零二二年十二月三十一 日止年度（「二零二二年財年」）之綜合業績，連同比較數字列載如下。 ...